Morgan Stanley’s Artelo Biosciences, Inc. Warrant ARTLW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-162
Closed -$3 8004
2024
Q1
$3 Sell
162
-162
-50% -$3 ﹤0.01% 7797
2023
Q4
$12 Buy
324
+162
+100% +$5 ﹤0.01% 7776
2023
Q3
$6 Hold
162
﹤0.01% 7575
2023
Q2
$8 Hold
162
﹤0.01% 7613
2023
Q1
$11 Hold
162
﹤0.01% 7660
2022
Q4
$6 Hold
162
﹤0.01% 7828
2022
Q3
$0 Hold
162
﹤0.01% 7964
2022
Q2
$0 Hold
162
﹤0.01% 8070
2022
Q1
$0 Hold
162
﹤0.01% 8192
2021
Q4
$0 Hold
162
﹤0.01% 8171
2021
Q3
$0 Hold
162
﹤0.01% 8066
2021
Q2
$0 Hold
162
﹤0.01% 7833
2021
Q1
$0 Hold
162
﹤0.01% 7600
2020
Q4
$0 Hold
162
﹤0.01% 7146
2020
Q3
$0 Buy
+162
New +$19 ﹤0.01% 6863

Morgan Stanley's ARTLW Position: Q2 2024 in Review

Morgan Stanley sold out of Artelo Biosciences, Inc. Warrant (ARTLW) in Q2 2024, closing a stake of 162 shares — an estimated $3 sold.

Morgan Stanley first reported a position in ARTLW in Q3 2020 and held it in 15 quarters. The position peaked at $12 in Q4 2023. 0 funds tracked by Wall St. Rank hold ARTLW as of Q2 2024.

  • Morgan Stanley reported no remaining Artelo Biosciences, Inc. Warrant position as of Q2 2024 after selling out during the quarter.
  • Morgan Stanley sold 162 Artelo Biosciences, Inc. Warrant shares in Q2 2024, an estimated $3.
  • Morgan Stanley first reported a position in Artelo Biosciences, Inc. Warrant in Q3 2020 and held it in 15 quarters.
  • Morgan Stanley's Artelo Biosciences, Inc. Warrant position peaked at $12 in Q4 2023.
  • 0 funds tracked by Wall St. Rank held Artelo Biosciences, Inc. Warrant as of Q2 2024.

Based on Morgan Stanley's 13F filing for Q2 2024, filed 14 Aug 2024.